RECORD // Company

Schrodinger, Inc.

Built 2026-11-22T00:24:47Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Matched by name only, not merged (6)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • SCHRODINGER, INC. · Ct business · same registered legal name as 'Schrodinger, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • SCHRODINGER · Epa echo · name equals 'Schrodinger' but other unrelated entities share it Possible match based on name, not a shared identifier. Compare the records. Compare
  • SCHRODINGER INC · Epa echo · same registered legal name as 'Schrodinger, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • SCHRODINGER, INC. · Ny corps · same registered legal name as 'Schrodinger, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • SCHRODINGER, L.L.C. · Ny corps · name equals 'Schrodinger' but other unrelated entities share it Possible match based on name, not a shared identifier. Compare the records. Compare
  • SCHRODINGER, INC. · USAspending · same registered legal name as 'Schrodinger, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare

5 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-04 · accession 0001490978-26-000076

ItemValuePeriodFormFiledAccessionReport
Revenue$64,491,0003 months ended 2026-09-3010-Q2026-11-040001490978-26-0000762026-11-22 00:24 UTCReport an error
Net income (loss)$-37,711,0003 months ended 2026-09-3010-Q2026-11-040001490978-26-0000762026-11-22 00:24 UTCReport an error
Cash and cash equivalents$246,983,000at 2026-09-3010-Q2026-11-040001490978-26-0000762026-11-22 00:24 UTCReport an error
Contract liabilities, current$97,674,000at 2026-09-3010-Q2026-11-040001490978-26-0000762026-11-22 00:24 UTCReport an error
Contract liabilities, noncurrent$53,560,000at 2026-09-3010-Q2026-11-040001490978-26-0000762026-11-22 00:24 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001490978
Ticker
SDGR
EIN
954284541
CUSIP
80810D103
Record ID
sx:sec:0001490978

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

40 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-16SEC EDGAR company profile2026-11-22 00:24 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-16SEC EDGAR company profile2026-11-22 00:24 UTCReport an error
State of incorporationDE2026-11-16SEC EDGAR company profile2026-11-22 00:24 UTCReport an error
Fiscal year end (MMDD)12312026-11-16SEC EDGAR company profile2026-11-22 00:24 UTCReport an error
Business address1540 BROADWAY, 24TH FLOOR, NEW YORK, NY, 100362026-11-16SEC EDGAR company profile2026-11-22 00:24 UTCReport an error
ExchangesNasdaq2026-11-16SEC EDGAR company profile2026-11-22 00:24 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$255,869,0002025-12-3110-K, XBRL Revenues2026-11-22 00:24 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-103,265,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-22 00:24 UTCReport an error
Total assets (at 2025-12-31)$726,160,0002025-12-3110-K, XBRL Assets2026-11-22 00:24 UTCReport an error
Stockholders' equity (at 2025-12-31)$364,053,0002025-12-3110-K, XBRL StockholdersEquity2026-11-22 00:24 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$230,517,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 00:24 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$13,899,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 00:24 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$1,442,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-22 00:24 UTCReport an error
Remaining performance obligation (at 2025-12-31)$43,053,0002025-12-3110-K, XBRL RevenueRemainingPerformanceObligation2026-11-22 00:24 UTCReport an error
Form D total offering amount (D/A filed 2019-05-08)$115,000,0002019-05-08D/A2026-11-22 00:24 UTCReport an error
Form D total amount sold (D/A filed 2019-05-08)$107,824,9872019-05-08D/A2026-11-22 00:24 UTCReport an error
Form D industry groupBiotechnology2019-05-08D/A2026-11-22 00:24 UTCReport an error
Form D revenue rangeDecline to Disclose2019-05-08D/A2026-11-22 00:24 UTCReport an error
Form D date of first sale2018-11-092019-05-08D/A2026-11-22 00:24 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-04)On November 4, 2026, Schrödinger, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended (the “Securities Act”)…2026-11-04SEC EDGAR 8-K 0001490978-26-000075 (text as filed, excerpt)2026-11-22 00:24 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-11-04)On November 4, 2026, the American Society of Hematology published the Company’s abstract reporting data from a Phase 1 study of SGR-1505, the Company’s MALT1 inhibitor (the “abstract”). The purpose of the information in this Item 7.01 is solely to correct certain information included in the abstract. The abstract stated that the Company has an ongoing combination study of SGR-1505 in patients with relapsed/refractory B cell malignancies. The Company has in fact not initiated a combination study of SGR-1505 under its FDA-cleared protocol and, as previously disclosed, is exploring strategic opportunities to continue development of SGR-1505. The information furnished under this Item 7.01 shall…2026-11-04SEC EDGAR 8-K 0001490978-26-000075 (text as filed, excerpt)2026-11-22 00:24 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-08-05)On August 5, 2026, Schrödinger, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act…2026-08-05SEC EDGAR 8-K 0001490978-26-000067 (text as filed, excerpt)2026-11-22 00:24 UTCReport an error
Employer name (as filed)Schrodinger, Inc.2026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-22 00:24 UTCReport an error
Certified LCAs92026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-22 00:24 UTCReport an error
Certified LCAs later withdrawn12026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-22 00:24 UTCReport an error
Total worker positions on certified LCAs92026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-22 00:24 UTCReport an error
Top job titles (title, LCA count)Senior Scientist I, Applications Science (2); Developer II (2); Principal Scientist I, Life Science Software (1); Senior Scientist II, Life Science Software (1); Senior Scientist I, Materials Science Modeling Services (1)2026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-22 00:24 UTCReport an error
Wage offered, annualized (n, min, median, max)median $148,100 (range $135,000-$182,800, 9 filings)2026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-22 00:24 UTCReport an error
Worksite statesCA; MA; NY2026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-22 00:24 UTCReport an error
Plan (pension, plan no. 001)SCHRODINGER, INC. 401(K) PROFIT SHARING PLAN & TRUST: 788 participants, assets $174,402,6992025-12-31DOL EBSA Form 5500 public datasets (dataset)2026-11-22 00:24 UTCReport an error
Largest institutional holder #1 (13F as filed): BlackRock, Inc.$170,978,0172026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:24 UTCReport an error
Largest institutional holder #2 (13F as filed): GATES FOUNDATION TRUST$113,452,0402026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:24 UTCReport an error
Largest institutional holder #3 (13F as filed): Rubric Capital Management LP$104,000,0002026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:24 UTCReport an error
Largest institutional holder #4 (13F as filed): VANGUARD PORTFOLIO MANAGEMENT LLC$61,545,1042026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:24 UTCReport an error
Largest institutional holder #5 (13F as filed): Sumitomo Mitsui Trust Group, Inc.$43,974,8242026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:24 UTCReport an error
Largest institutional holder #6 (13F as filed): Amova Asset Management Americas, Inc.$43,947,7622026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:24 UTCReport an error
Largest institutional holder #7 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$43,731,1712026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:24 UTCReport an error
Largest institutional holder #8 (13F as filed): STATE STREET CORP$37,347,9932026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:24 UTCReport an error
Largest institutional holder #9 (13F as filed): UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC$36,099,1312026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:24 UTCReport an error
Largest institutional holder #10 (13F as filed): ARK Investment Management LLC$35,002,7972026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:24 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.